文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATATE PET/CT 在临床、影像和/或生化怀疑神经内分泌肿瘤患者初步诊断中的应用

68 Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and/or Biochemical Suspicion of a Neuroendocrine Tumor.
PubMed 文献 · Clin Nucl Med · 2023-09-07

该研究为前瞻性单臂注册研究(NCT03873870)的一部分,纳入220例临床、影像和/或生化怀疑但未确诊神经内分泌肿瘤的患者,评估68Ga-DOTATATE PET/CT的阳性检出率。结果显示总体阳性率为60%(132/220),影像学可疑异常者中71.9%(123/171)确认存在生长抑素受体过表达肿瘤,胰腺和小肠/肠系膜病灶阳性率最高,而仅有生化/临床怀疑者阳性率为18.4%(9/49)。

要点

  • 220例怀疑NET患者中,68Ga-DOTATATE PET/CT总体阳性率为60%(132/220)。
  • 影像学可疑异常者中71.9%(123/171)确认生长抑素受体过表达肿瘤。
  • 胰腺病灶阳性率81.2%(78/96),小肠/肠系膜66.7%(38/57)。

核心结论

  • 68Ga-DOTATATE PET/CT在约3/4影像学怀疑NET的患者中为阳性,胰腺和小肠/肠系膜肿块检出率最高,在约1/6生化/临床怀疑NET的患者中为阳性。

研究设计与样本

  • 前瞻性单臂注册研究(NCT03873870)的一部分,纳入2019年4月至2022年3月间220例因初始诊断未确诊NET而转诊的患者,平均年龄59.5±16.1岁。
  • 纳入标准为生物标志物升高和/或临床表现怀疑NET且常规横断面影像阴性,或常规影像发现可疑NET病灶但不适合活检;组织学确诊NET者排除。

主要发现

  • 总体132/220例(60%)68Ga-DOTATATE PET/CT阳性。
  • 影像学可疑异常患者中123/171例(71.9%)确认存在2型生长抑素受体过表达肿瘤。
  • 胰腺、小肠/肠系膜、肾上腺和其他部位阳性率分别为78/96(81.2%)、38/57(66.7%)、7/7(100%)和1/11(9.1%)。
  • 仅有生化/临床怀疑NET的患者中9/49例(18.4%)68Ga-DOTATATE PET/CT阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess the yield of somatostatin receptor PET in patients with clinical, imaging, and/or biochemical suspicion of a neuroendocrine tumor (NET). PATIENTS AND METHODS: This analysis includes patients referred for the initial diagnosis of an unconfirmed NET, as part of a prospective, single-arm registry study (NCT03873870) assessing the utility of 68 Ga-DOTATATE PET/CT in the management of NETs. Inclusion criteria to this cohort consisted of elevated biomarkers and/or clinical presentation suspicious for a NET, with negative conventional cross-sectional imaging, or presence of a lesion suspicious for a NET on conventional imaging, not amenable for biopsy. Patients with histological confirmation of a NET were excluded. RESULTS: There were 220 patients included between April 2019 and March 2022 with a mean age ± SD of 59.5 ± 16.1 years with biochemical, morphological, and/or clinical suspicion of a NET. Overall, 132/220 patients (60%) had a positive 68 Ga-DOTATATE PET/CT. 68 Ga-DOTATATE PET/CT confirmed a type 2 somatostatin receptor overexpressing tumor in 123/171 (71.9%) of patients with a radiographically suspicious abnormality. The positivity rate for pancreatic, small bowel/mesenteric, adrenal, and other sites was 78/96 (81.2%), 38/57 (66.7%), 7/7 (100%), and 1/11 (9.1%), respectively. 68 Ga-DOTATATE PET/CT was positive in 9/49 (18.4%) of those with a biochemical and/or clinical suspicion of a NET. CONCLUSIONS: 68 Ga-DOTATATE PET/CT is positive in nearly 3 of 4 patients with morphological suspicion of a NET, with the highest yield in those with pancreatic and small bowel or mesenteric masses, and in approximately 1 of 6 patients with biochemical and/or clinical suspicion of a NET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Metser U, Ezzat S, Singh S, et al. 68 Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and/or Biochemical Suspicion of a Neuroendocrine Tumor. Clin Nucl Med. 2023. PMID: 37703482. doi:10.1097/RLU.0000000000004829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。